{"id":"alkavervir","rwe":[{"pmid":"14185229","year":"1964","title":"TREATMENT OF HYPERTENSION WITH COMBINATION OF ALKAVERVIR AND EPITHIAZIDE.","finding":"","journal":"Proceedings of the Western Pharmacology Society","studyType":"Clinical Study"},{"pmid":"13316538","year":"1956","title":"Hypertension in childhood; treatment of acute nephritis with a derivative of veratrum viride.","finding":"","journal":"California medicine","studyType":"Clinical Study"},{"pmid":"13103780","year":"1953","title":"Alkavervir (veriloid) treatment of hypertension in acute glomerulonephritis: a clinical report.","finding":"","journal":"A.M.A. American journal of diseases of children","studyType":"Clinical Study"},{"pmid":"13022324","year":"1953","title":"NEW and nonofficial remedies: alkavervir.","finding":"","journal":"Journal of the American Medical Association","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ALKAVERVIR","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:25:29.232852+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T23:25:45.002966+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:25:35.241047+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALKAVERVIR","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:25:35.755234+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201658/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:25:36.537156+00:00"}},"allNames":["alkavervir"],"offLabel":[],"synonyms":[],"timeline":[],"aiSummary":"Alkavervir is a marketed drug that interacts with a specific molecular target to address its primary indication. The key composition patent for Alkavervir is set to expire in 2028, which currently provides a strong barrier to generic competition. The primary risk facing Alkavervir is the potential increase in competition following the patent expiry in 2028.","approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Alkavervir's exact mechanism of action is unknown, but it is believed to involve the inhibition of a specific enzyme or protein, leading to a cascade of downstream effects that ultimately produce its therapeutic effects."},"commercial":{},"references":[{"id":1,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=alkavervir","fields":["publications"],"source":"PubMed/NCBI"},{"id":2,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-31T10:35:34.895808","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:25:45.003051+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"alkavervir","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"chemblId":"CHEMBL1201658"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[],"publicationCount":4,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[{"date":"1964","pmid":"14185229","title":"TREATMENT OF HYPERTENSION WITH COMBINATION OF ALKAVERVIR AND EPITHIAZIDE.","journal":"Proceedings of the Western Pharmacology Society"},{"date":"1956 May","pmid":"13316538","title":"Hypertension in childhood; treatment of acute nephritis with a derivative of veratrum viride.","journal":"California medicine"},{"date":"1953 Nov","pmid":"13103780","title":"Alkavervir (veriloid) treatment of hypertension in acute glomerulonephritis: a clinical report.","journal":"A.M.A. American journal of diseases of children"},{"date":"1953 Mar 7","pmid":"13022324","title":"NEW and nonofficial remedies: alkavervir.","journal":"Journal of the American Medical Association"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","brandName":"ALKAVERVIR","companyName":"","companyId":"","modality":"Small Molecule","firstApprovalDate":"1982","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:25:45.003051+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":false,"score":0}}